Article

The Future of HIV Highlights Specialty Pharmacy Week in Review

Author(s):

Lauren Santye, Assistant Editor

Top articles of the week from Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/the-future-of-hiv-highlights" target="_blank">View the story "The Future of HIV Highlights Specialty Pharmacy Week in Review" on Storify</a>]

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Related Content
Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
June 5th 2025

ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Traveler at an airport -- Image credit: Yakobchuk Olena | stock.adobe.com
June 5th 2025

Amid Measles Outbreak, CDC Advises International Travelers to Receive MMR Immunization

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Women feeling unwell and sinus on gray background - Image credit: eddows | stock.adobe.com
June 4th 2025

Study: LYR-210 Shows Promise in Chronic Rhinosinusitis with Nasal Polyps

Kennedy Ferruggia, Assistant Editor
Molecular biologist holding blood sample for EGFR mutation test for the diagnosis of lung disease. Epidermal Growth Factor Receptor.
June 4th 2025

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

Luke Halpern, Assistant Editor